A5003059298- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Kruppel-like factors research
Albert Einstein College of Medicine
2022
Abstract Purpose: The Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are characterized by JAK/STAT pathway activation. JAK inhibitors approved for MPN treatment, but persistence has been observed, due to reactivation. Experimental Design: Using patient samples, JAK2-mutated cell lines, mouse models, we examined both the efficacy mechanism which crizotinib, ALK/MET/RON/ROS1 inhibitor treatment of...
<p>Table S2</p>
<p>Table S3</p>
<p>Supplementary Figures and figure legends</p>
<p>Table S2</p>
<p>Table S3</p>
<p>Supplementary Figures and figure legends</p>
<div>AbstractPurpose:<p>The Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are characterized by JAK/STAT pathway activation. JAK inhibitors approved for MPN treatment, but persistence has been observed, due to reactivation.</p>Experimental Design:<p>Using patient samples, JAK2-mutated cell lines, mouse models, we examined both the efficacy mechanism which crizotinib,...
<div>AbstractPurpose:<p>The Philadelphia chromosome–negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are characterized by JAK/STAT pathway activation. JAK inhibitors approved for MPN treatment, but persistence has been observed, due to reactivation.</p>Experimental Design:<p>Using patient samples, JAK2-mutated cell lines, mouse models, we examined both the efficacy mechanism which crizotinib,...